Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880401 | 0.81 | HCRTR1 (0.42) | HCRTR1HCRTR2CYP2A6DHODHATR | |
| SCHEMBL13097147 | 0.77 | CYP2A6 (0.44) | HCRTR1HCRTR2CYP2A6DHODHCYP11B2 | |
| SCHEMBL440917 | 0.76 | HCRTR2 (0.44) | HCRTR1HCRTR2DHODHCYP11B2CYP11B1 | |
| SCHEMBL30862152 | 0.70 | KDM4E (0.36) | PIM1PIM2 | |
| SCHEMBL8617736 | 0.67 | CYP2D6 (0.43) | CYP2A6DHODHPIM1PIM2CYP3A4 | |
| SCHEMBL20848300 | 0.66 | CYP11B2 (0.36) | CYP2A6CYP11B2CYP11B1ATR | |
| SCHEMBL451554 | 0.65 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP2A6CYP11B2CYP11B1 | |
| SCHEMBL7877771 | 0.65 | HCRTR1 (0.57) | HCRTR1HCRTR2DHODHCYP11B2CYP11B1 | |
| SCHEMBL25559975 | 0.64 | HTT (0.36) | HCRTR1HCRTR2PIM1KDR | |
| SCHEMBL469153 | 0.64 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP11B2CYP11B1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885CYP2A6 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.